{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:54:29Z","timestamp":1794322469350,"version":"4.9.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Project of Shanghai Public Health Clinical Center","award":["KY-GW-2025-28"],"award-info":[{"award-number":["KY-GW-2025-28"]}]},{"name":"Clinical Research Project of Shanghai Public Health Clinical Center","award":["KY-GW-2024-01"],"award-info":[{"award-number":["KY-GW-2024-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10874-x","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T17:39:27Z","timestamp":1743874767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical efficacy of linezolid in the treatment of tuberculous meningitis: a retrospective analysis and literature review"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhen-Tao","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"10874_CR1","unstructured":"World Health Organization. Global tuberculosis report 2024 [EB\/OL]. [2024-10-29]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024. [Accessed 2025-02-01]."},{"key":"10874_CR2","doi-asserted-by":"publisher","first-page":"1048653","DOI":"10.3389\/fphar.2022.1048653","volume":"13","author":"NF Maranchick","year":"2022","unstructured":"Maranchick NF, Alshaer MH, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, et al. Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis. Front Pharmacol. 2022;13:1048653. https:\/\/doi.org\/10.3389\/fphar.2022.1048653.","journal-title":"Front Pharmacol"},{"key":"10874_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1186\/s12879-021-06705-4","volume":"21","author":"MT Fang","year":"2021","unstructured":"Fang MT, Su YF, An HR, Zhang PZ, Deng GF, Liu HM, et al. Decreased mortality seen in rifampicin\/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China. BMC Infect Dis. 2021;21:1015. https:\/\/doi.org\/10.1186\/s12879-021-06705-4.","journal-title":"BMC Infect Dis"},{"key":"10874_CR4","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.tube.2023.102351","volume":"142","author":"A Sahib","year":"2023","unstructured":"Sahib A, Bhatia R, Srivastava MVP, Singh MB, Komakula S, Vishnu VY, et al. Escalate: linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial. Tuberculosis (Edinb). 2023;142:102351. https:\/\/doi.org\/10.1016\/j.tube.2023.102351.","journal-title":"Tuberculosis (Edinb)"},{"key":"10874_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/INF.0000000000001114","volume":"35","author":"H Li","year":"2016","unstructured":"Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J. 2016;35:607\u201310. https:\/\/doi.org\/10.1097\/INF.0000000000001114.","journal-title":"Pediatr Infect Dis J"},{"key":"10874_CR6","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1128\/AAC.02784-14","volume":"58","author":"F Sun","year":"2014","unstructured":"Sun F, Ruan Q, Wang J, Chen S, Jin J, Shao L, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother. 2014;58:6297\u2013301. https:\/\/doi.org\/10.1128\/AAC.02784-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"10874_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","volume":"10","author":"S Marais","year":"2010","unstructured":"Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10:803\u201312. https:\/\/doi.org\/10.1016\/S1473-3099(10)70138-9.","journal-title":"Lancet Infect Dis"},{"key":"10874_CR8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJMoa040573","volume":"351","author":"GE Thwaites","year":"2004","unstructured":"Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741\u201351. https:\/\/doi.org\/10.1056\/NEJMoa040573.","journal-title":"N Engl J Med"},{"key":"10874_CR9","doi-asserted-by":"publisher","first-page":"CD012091","DOI":"10.1002\/14651858.CD012091.pub2","volume":"9","author":"S Jullien","year":"2016","unstructured":"Jullien S, Ryan H, Modi M, Bhatia R. Six months therapy for tuberculous meningitis. Cochrane Database Syst Rev. 2016;9:CD012091. https:\/\/doi.org\/10.1002\/14651858.CD012091.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"10874_CR10","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/cid\/ciab992","volume":"75","author":"RR Kempker","year":"2022","unstructured":"Kempker RR, Smith AGC, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, et al. Cycloserine and linezolid for tuberculosis meningitis: Pharmacokinetic evidence of potential usefulness. Clin Infect Dis. 2022;75:682\u20139. https:\/\/doi.org\/10.1093\/cid\/ciab992.","journal-title":"Clin Infect Dis"},{"key":"10874_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/infdis\/jiad413","volume":"229","author":"N Abdelgawad","year":"2024","unstructured":"Abdelgawad N, Wasserman S, Abdelwahab MT, Davis A, Stek C, Wiesner L, et al. Linezolid population Pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. J Infect Dis. 2024;229:1200\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiad413.","journal-title":"J Infect Dis"},{"key":"10874_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.5114\/aoms\/189905","volume":"20","author":"X Liu","year":"2024","unstructured":"Liu X, Tang D, Qi M, He JQ. Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis. Arch Med Sci. 2024;20:1038\u201342. https:\/\/doi.org\/10.5114\/aoms\/189905.","journal-title":"Arch Med Sci"},{"key":"10874_CR13","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902. https:\/\/doi.org\/10.3389\/fphar.2024.1338902.","journal-title":"Front Pharmacol"},{"key":"10874_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly Drug-Resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"key":"10874_CR15","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/jac\/dks078","volume":"67","author":"WJ Koh","year":"2012","unstructured":"Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, et al. Daily 300\u00a0mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother. 2012;67:1503\u20137. https:\/\/doi.org\/10.1093\/jac\/dks078.","journal-title":"J Antimicrob Chemother"},{"key":"10874_CR16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","volume":"40","author":"G Sotgiu","year":"2012","unstructured":"Sotgiu G, Centis R, D\u2019Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430\u201342. https:\/\/doi.org\/10.1183\/09031936.00022912.","journal-title":"Eur Respir J"},{"key":"10874_CR17","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clin Infect Dis. 2016;63:e147\u201395. https:\/\/doi.org\/10.1093\/cid\/ciw376.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10874-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10874-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T17:39:28Z","timestamp":1743874768000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10874-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10874"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10874-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"20 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of the Shanghai Public Health Clinical Center (Approval Number: 2024-S002-01). The need for informed consent was waived by the Ethics Committee of the Shanghai Public Health Clinical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors confirm that no AI or AI-assisted technologies were used in the creation of this manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"467"}}